Medios AG Logo

Medios AG

Compounding patient-specific therapies and supplying specialty pharma for complex conditions.

ILM1 | F

Overview

Corporate Details

ISIN(s):
DE000A1MMCC8 (+1 more)
LEI:
391200Z7Z09IHDBT2L23
Country:
Germany
Address:
Heidestraße 9, 10557 Berlin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Medios AG is a leading European specialty pharmaceutical company focused on advancing individualized medicine. The company's core business involves the compounding of patient-specific therapies and the supply of specialty pharma solutions. It serves a diverse client base, including pharmacies, medical specialists, hospitals, and pharmaceutical companies, ensuring reliable access to innovative treatments for complex and chronic conditions. With a strong focus on therapeutic areas such as oncology, neurology, and autoimmune diseases, Medios pioneers the development and distribution of advanced therapies and biotechnological precision medicine. By integrating pharmaceutical supply with specialized compounding services, the company plays a crucial role in making personalized treatments accessible to patients.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-03 09:57
Board/Management Information
Thomas Meier becomes new CEO of Medios AG
English 9.1 KB
2025-10-24 10:45
Declaration of Voting Results & Voting Rights Announcements
English 12.3 KB
2025-09-04 15:00
Declaration of Voting Results & Voting Rights Announcements
English 12.3 KB
2025-08-28 10:15
Declaration of Voting Results & Voting Rights Announcements
English 13.5 KB
2025-08-27 10:37
Declaration of Voting Results & Voting Rights Announcements
English 13.2 KB
2025-08-13 07:37
Earnings Release
Medios accelerates growth in the first half of 2025 and significantly increases…
English 20.0 KB
2025-08-13 00:00
Interim Report
Half-yearly financial report 2025
English 500.4 KB
2025-07-18 11:41
Major Shareholding Notification
English 5.4 KB
2025-07-11 09:55
Transaction in Own Shares
Medios successfully completes public share buyback offer
English 11.0 KB
2025-06-18 19:16
Transaction in Own Shares
Medios adopts public share buyback offer for up to 1 million shares at a price …
English 11.8 KB
2025-05-27 16:06
Post-Annual General Meeting Information
Medios AG Annual General Meeting 2025: Shareholders approve all proposed resolu…
English 10.1 KB
2025-05-14 07:50
Earnings Release
Medios starts 2025 financial year successfully with significant increase in ear…
English 20.7 KB
2025-05-13 00:00
Quarterly Report
Q1 statement / Q1 financial report 2025
English 10.1 MB
2025-05-12 18:58
Board/Management Information
Medios repositions itself for the next phase of its corporate development
English 12.7 KB
2025-04-14 15:06
Pre-Annual General Meeting Information
Medios AG: Bekanntmachung der Einberufung zur Hauptversammlung am 27.05.2025 in…
German 256.2 KB

Automate Your Workflow. Get a real-time feed of all Medios AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Medios AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Medios AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-19 van Rietschoten, Constantijn Board Buy None 162,805.82 EUR
2023-06-28 Prußeit, Christoph Board Buy None 39,100.00 EUR
2021-12-09 Miehler, Mi-Young Board Other None 3,550,000.00 EUR
2021-12-09 Prußeit, Christoph Board Other None 1,775,000.00 EUR
2021-12-09 Miehler, Mi-Young Board Other None 700,000.00 EUR
2021-12-09 Prußeit, Christoph Board Other None 350,000.00 EUR

Peer Companies

Company Country Ticker View
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America APRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.